Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Healthcare Shares
3 junior ASX healthcare shares with explosive growth potential
Share Market News
ASX 200 drops 1.1%: Big four banks fall, Resolute rockets, Afterpay tumbles
Share Fallers
Why Afterpay, BHP, Cann, & Mesoblast shares are tumbling lower
Healthcare Shares
Why Mesoblast might be the best ASX healthcare growth share to own right now
Share Market News
4 exciting ASX biotech shares surging higher today
Share Gainers
Why Afterpay, Ecofibre, Mesoblast, & Zip Co shares are racing higher
Share Market News
Mesoblast share price climbs 9% on FDA meeting
Share Market News
Why the Mesoblast share price gained 58% in the first half of 2020
Share Market News
5 of the worst performing ASX shares from last week
Share Market News
Why these 9 ASX shares have doubled in value in the past year
⏸️ TMF AMP
ASX 200 Weekly Wrap: Blue chip shares pull ASX 200 back over 6,000 points
Share Fallers
These were the worst performing ASX 200 shares last week
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
